Inventiva (IVA) Income towards Parent Company (2019 - 2025)
Inventiva's (IVA) quarterly Income towards Parent Company came in at $880664.6 in Q2 2025, up 1268.27% year-on-year from $64363.5 in Q2 2024, and up 1277.33% quarter-over-quarter from -$74801.7 in Q4 2024.
Inventiva (IVA) Income towards Parent Company (2019 - 2025) Analysis & Trends
Inventiva's Income towards Parent Company history runs 7 years deep, the most recent figure standing at $880664.6 for Q2 2025.
- On a quarterly basis, Income towards Parent Company rose 1268.27% year-over-year to $880664.6 in Q2 2025; TTM through Dec 2025 was $730480.8, a 284.7% increase from a year earlier, with the FY2025 full-year figure at -$411.9 million, down 55275.39% from the prior year.
- Income towards Parent Company grew to $880664.6 in Q2 2025 per IVA's latest filing, from -$74801.7 in the prior quarter.
- Across five years, Income towards Parent Company topped out at $880664.6 in Q2 2025 and bottomed at -$11.9 million in Q2 2021.
- The 5-year median for Income towards Parent Company is -$178852.7 (2022), against an average of -$2.1 million.
- Across the five-year window, Income towards Parent Company dropped 23.09% in 2021 and jumped 1268.27% in 2025, its largest moves.
- Year by year, Income towards Parent Company stood at -$11.9 million in 2021, then jumped by 98.03% to -$234656.9 in 2022, then decreased by 4.54% to -$245314.3 in 2023, then surged by 69.51% to -$74801.7 in 2024, then soared by 1277.33% to $880664.6 in 2025.
- Per Business Quant, the three latest IVA Income towards Parent Company figures stand at $880664.6 (Q2 2025), -$74801.7 (Q4 2024), and -$75382.1 (Q2 2024).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Inventiva | 854.62 Mn | 854.62 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 880,664.64 |
| Dec 31, 2024 | -74,801.68 |
| Jun 30, 2024 | -75,382.13 |
| Dec 31, 2023 | -245,314.30 |
| Jun 30, 2023 | -123,048.46 |
| Dec 31, 2022 | -234,656.89 |
| Jun 30, 2021 | -11.94 Mn |
| Mar 31, 2021 | -5.24 Mn |
| Dec 31, 2020 | -35.43 Mn |
| Jun 30, 2020 | -9.70 Mn |
| Mar 31, 2020 | -7.48 Mn |
| Dec 31, 2019 | -33.34 Mn |